title: Powerful technique to test selectivity of agents acting on cardiac ion channels: the action potential voltage-clamp.
abstract: Action potential voltage-clamp (APVC) is a technique to visualize the profile of various currents during the cardiac action potential. This review summarizes potential applications and limitations of APVC, the properties of the most important ion currents in nodal, atrial, and ventricular cardiomyocytes. Accordingly, the profiles ("fingerprints") of the major ion currents in canine ventricular myocytes, i.e. in cells of a species having action potential morphology and set of underlying ion currents very similar to those found in the human heart, are discussed in details. The degree of selectivity of various compounds, which is known to be a critical property of drugs used in APVC experiments, is overviewed. Thus the specificity of agents known to block sodium (tetrodotoxin, saxitoxin), potassium (chromanol 293B, HMR 1556, E-4031, dofetilide, sotalol, 4-aminopyridine, BaCl(2)), calcium (nifedipine, nisolpidine, nicardipine, diltiazem, verapamil, gallopamil), and chloride (anthracene-9-carboxylic acid, DIDS) channels, the inhibitor of the sodium-calcium exchanger (SEA0400), and the activator of sodium current (veratridine) are accordingly discussed. Based on a theory explaining how calcium current inhibitors block calcium channels, the structural comparison of the studied substances usually confirmed the results of the literature. Using these predictions, a hypothetical super-selective calcium channel inhibitor structure was designed. APVC is a valuable tool not only for studying the selectivity of the known ion channel blockers, but is also suitable for safety studies to exclude cardiac ion channel actions of any agent under development.
authors.affiliation: Department of Physiology, University of Debrecen, Nagyerdei krt. 98. H-4012 Debrecen, Hungary. norbi@phys.dote.hu
authors.forename: N
authors.initials: N
authors.lastname: Szentandrássy
authors.forename: D
authors.initials: D
authors.lastname: Nagy
authors.forename: F
authors.initials: F
authors.lastname: Ruzsnavszky
authors.forename: G
authors.initials: G
authors.lastname: Harmati
authors.forename: T
authors.initials: T
authors.lastname: Bányász
authors.forename: J
authors.initials: J
authors.lastname: Magyar
authors.forename: A J
authors.initials: AJ
authors.lastname: Szentmiklósi
authors.forename: P P
authors.initials: PP
authors.lastname: Nánási
mesh_terms: D000200:Action Potentials; D000818:Animals; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002317:Cardiovascular Agents / Q000494:pharmacology*; D004285:Dogs; D006801:Humans; D007473:Ion Channels / Q000378:metabolism / Q000502:physiology*; D032383:Myocytes, Cardiac / Q000187:drug effects*; D018408:Patch-Clamp Techniques; D026902:Potassium Channel Blockers / Q000494:pharmacology; D026941:Sodium Channel Blockers / Q000494:pharmacology
chemical_list: D002121:Calcium Channel Blockers; D002317:Cardiovascular Agents; D007473:Ion Channels; D026902:Potassium Channel Blockers; D026941:Sodium Channel Blockers